|Bid||0.00 x 0|
|Ask||20.33 x 200|
|Day's Range||17.66 - 19.05|
|52 Week Range||8.10 - 31.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.46|
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.
In the future, Voyager is expected to earn collaboration revenues from Sanofi and AbbVie. This increase of $20 million was primarily attributable to a jump in external research costs and employee expenses. Its external research costs rose from $20.4 million in 2016 to $33.8 million in 2017.
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications, including advanced Parkinson’s disease, amyotrophic lateral sclerosis (or ALS), Huntington’s disease, and Alzheimer’s disease. Voyager Therapeutics’ most advanced clinical candidate is VY-AADC for the treatment of advanced Parkinson’s disease.
The Cambridge, Massachusetts-based company said it had a loss of 40 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
VY-AADC for advanced Parkinson’ s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year. Two IND filings expected from the ALS, Huntington’ s disease and ...
Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Stock Monitor: Editas Medicine Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’ s disease medications; one-time administrations of VY-AADC ...
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
CAMBRIDGE, Mass., Feb. 27, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its fourth quarter ...
CAMBRIDGE, Mass., Feb. 26, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation ...
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
Stock Monitor: Bioverativ Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
Voyager continued rocketing Wednesday after announcing a collaboration with AbbVie to develop an Alzheimer's disease drug.
AbbVie (NYSE:ABBV) and Voyager Therapeutics, Inc. (NASDAQ:VYGR) are big movers in the biotechnology space during the middle of this week, with the two companies putting out some potentially game-changing news (and the news is interrelated – more on this shortly) and picking up some action in their market capitalization on the back of the development. […] The post Here’s What The AbbVie and Voyager Therapeutics Deal Really Means appeared first on Market Exclusive.
Voyager Therapeutics said Tuesday that it will work with AbbVie to develop gene therapy treatments for Alzheimer’s disease in a deal worth at least $69 million for the Cambridge biotech. The announcement by Voyager (VYGR) and Chicago-based AbbVie (ABBV) comes as drug developers are exploring new approaches to Alzheimer’s following a string of recent clinical setbacks. Gene therapies — drugs that work by inserting healthy genes into a person’s cells to replace faulty or missing ones — offer one intriguing avenue.
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. This collaboration combines AbbVie's monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager's gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau. Voyager to receive $69 million upfront payment and potentially ...
CAMBRIDGE, Mass., Feb. 07, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation ...
Voyager Therapeutics Inc (NASDAQ: VYGR ) faded this week on news of a CEO transition, but the firm caught a boost Friday from a new advocate. The Rating Morgan Stanley analyst Matthew Harrison initiated ...